课题基金 / 基金详情

Robust 1H MRSI of GABA, Glutamate, Glutamine, and Glutathione

Robust 1H MRSI of GABA, Glutamate, Glutamine, and Glutathione
GABA、谷氨酸、谷氨酰胺和谷胱甘肽的稳定 1H MRSI
批准号:
9910230
负责人:
Daniel M Spielman
金额:
$42.02万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2017
资助国家:
美国
项目状态:
已结题
起止时间:
2017-06-15 至 2022-04-30
关键词:
AdolescentAffectAgeAnimal ModelAnteriorAntioxidantsArchitectureAreaAuditory areaAutopsyBehaviorBiochemical PathwayBiological MarkersBrainBrain DiseasesBrain regionCharacteristicsChildClinicalClinical ResearchCompanionsConsumptionDataData SetDependenceDevelopmentDiagnosisDiseaseEquilibriumEtiologyEvaluationExhibitsFrequenciesFunctional disorderFutureGenderGenerationsGeneticGlutamatesGlutamineGlutathioneGoalsGrantHeterogeneityHumanImaging DeviceImaging TechniquesIndividualInvestigationLightMagnetic Resonance SpectroscopyMapsMeasurementMeasuresMethodsMonitorMotor CortexNeurobiologyNeurodevelopmental DisorderNeuronsNeuropsychological TestsNeurotransmittersObsessive compulsive behaviorPathologyPatientsPatternPhysiologic pulseProceduresProtonsPsychopathologyPublishingReportingResearchResearch PersonnelResolutionScanningSeveritiesSideSignal TransductionSliceSocial InteractionStereotypingStructure-Activity RelationshipTechniquesTestingTherapeutic InterventionTimeUnited StatesUnited States National Institutes of HealthVariantVisual Cortexadolescent patientauditory thalamusautism spectrum disorderbasebrain abnormalitiesbrain metabolismcognitive abilitydata acquisitiondesigngamma-Aminobutyric Acidimaging modalityimaging studyin vivoin vivo magnetic resonance spectroscopyinnovationinsightinterestmacromoleculemagnetic fieldmagnetic resonance spectroscopic imagingneurochemistryneurodevelopmentneuroimagingneuropsychiatric disorderneurotransmitter antagonistnon-invasive imagingnovelnovel strategiespatient populationresponsesocial communicationsocioeconomicstemporal measurementtheoriestool

项目摘要

项目成果

Daniel M Spielman的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
Project Abstract Understanding neurotransmitter activity is fundamental to elucidating normal and diseased neuronal function, with glutamate (Glu) and γ-aminobutyric acid (GABA) being the brain's primary excitatory and inhibitory neurotransmitters. Such understanding is particularly critical in autism spectrum disorder (ASD), a set of neurodevelopment disorders characterized by persistent deficits in social communication and restricted, repetitive, and stereotyped patterns of behavior. Although varying in presentation and severity, ASD occurs in all ethnic and socioeconomic groups, has a lifelong duration, and affects an estimated 1 out of 68 children in the United States. Unfortunately, the etiologies of these disorders are not fully understood, and this technical development proposal to develop novel non-invasive imaging tools for studying ASD brain neurochemical biomarkers is in response to NIH PA 10-158 “Research on Autism Spectrum Disorders”. The innovations to be evaluated under this project will help not only investigating ASD, but also other neuropsychiatric and neurodevelopmental disorders where advanced imaging techniques are needed. Despite the heterogeneity of ASD, patients may share final common biochemical pathways and potentially be responsive to similar treatments, and ASD is now hypothesized to result from an imbalance between excitatory and inhibitory neurotransmitters. Known as the “E/I balance” theory, findings from both animal models and humans suggest ASD is characterized by hyper-excitability in critical brain regions due to increased Glu and/or decreased GABA. While in vivo evidence of such neurochemical imbalances is beginning to emerge through the use of J-edited 1H magnetic resonance spectroscopy (MEGA-PRESS being the current method of choice) robust in vivo measurements are time-consuming and problematic. Glu measurement is straightforward, but separation from closely related glutamine (Gln) is difficult. Furthermore, co-edited macromolecules (MMs) overlap the targeted GABA signal and account for 40-60% of the detected signal, leading investigators to refer to the resulting data as GABA+MMs or simply GABA+. MRS-detected MMs are also reported to exhibit regional variations, variability across normal subjects, and dependence on both age and pathology. Even for single-voxel studies, prior proposed MM-suppression techniques are not widely used, being either time-consuming or highly sensitive to B0 magnetic field variations. This proposal seeks to overcome these limitations via the systematic design, implementation, and testing of robust MM-suppressed J-edited single-voxel (Aims 1 and 2) and multi-voxel (Aim 3) sequences to measure these targeted neurochemicals, yielding time-efficient measurements from multiple brain regions. These new tools will be used to assess neurochemical imbalances in adolescent patients diagnosed with ASD (Aim 4).
期刊论文(1)
专著(0)
科研奖励(0)
会议论文
DOI: 10.1002/nbm.4752
发表时间: 2022-09
期刊: NMR in biomedicine
影响因子: 2.9
作者: []
通讯作者:
Enhanced Deuterium Metabolic Imaging (DMI) of Metabolic Reprogramming in Brain Tumors
  • 批准号:
    10593853
  • 项目类别:
  • 资助金额:
    $61.04万
  • 财政年份:
    2023
  • 负责人:
    Daniel M Spielman
  • 依托单位:
Imaging Brain Metabolism Using MRS of Hyperpolarized 13C-Pyruvate
  • 批准号:
    9269573
  • 项目类别:
  • 资助金额:
    $50.4万
  • 财政年份:
    2015
  • 负责人:
    Daniel M Spielman
  • 依托单位:
Novel MRS methods for measuring brain energetics and neurotransmitter cycling
  • 批准号:
    8990476
  • 项目类别:
  • 资助金额:
    $20.07万
  • 财政年份:
    2015
  • 负责人:
    Daniel M Spielman
  • 依托单位:
Hyperpolarizer for 13C MR Metabolic Imaging of Human Subjects and Animal Models
  • 批准号:
    8333704
  • 项目类别:
  • 资助金额:
    $200.0万
  • 财政年份:
    2013
  • 负责人:
    Daniel M Spielman
  • 依托单位:
海外基金